NOVOGEN BEGINS SECOND PHASE I TRIAL OF ANTI-INFLAMMATORY

Novogen's investigational anti-inflammatory compound, NV-52, is entering its second human clinical study following the successful completion of toxicology testing. NV-52 is being developed to target inflammatory bowel disease.

The Phase Ib study was cleared to begin following the successful completion of a Phase Ia study that confirmed the bioavailability of the drug in oral form and its safety when administered at an acute dose. Twelve volunteers will be given the drug in a repeat dose over seven days.

The study seeks to extend the safety data by looking at the use of the drug on a long-term basis, as well as testing the ability of the drug to change certain inflammatory markers in the serum. Researchers hope this will provide a platform to test the drug patients with inflammatory bowel disease.